[go: up one dir, main page]

BRPI0500393B8 - forma cristalina ii de agomelatina e sua composição farmacêutica - Google Patents

forma cristalina ii de agomelatina e sua composição farmacêutica

Info

Publication number
BRPI0500393B8
BRPI0500393B8 BRPI0500393A BRPI0500393A BRPI0500393B8 BR PI0500393 B8 BRPI0500393 B8 BR PI0500393B8 BR PI0500393 A BRPI0500393 A BR PI0500393A BR PI0500393 A BRPI0500393 A BR PI0500393A BR PI0500393 B8 BRPI0500393 B8 BR PI0500393B8
Authority
BR
Brazil
Prior art keywords
agomelatine
crystalline form
pharmaceutical composition
synthesis
drugs
Prior art date
Application number
BRPI0500393A
Other languages
English (en)
Inventor
Chapuis Geneviève
Thominot Gilles
Damien Gérard
Gonzalez Blanco Isaac
Souvie Jean-Claude
Horvath Stéphane
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34685019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0500393(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Priority to BR122018068717A priority Critical patent/BR122018068717B8/pt
Publication of BRPI0500393A publication Critical patent/BRPI0500393A/pt
Priority to TW095120045A priority patent/TW200716511A/zh
Publication of BRPI0500393B1 publication Critical patent/BRPI0500393B1/pt
Publication of BRPI0500393B8 publication Critical patent/BRPI0500393B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F03—MACHINES OR ENGINES FOR LIQUIDS; WIND, SPRING, OR WEIGHT MOTORS; PRODUCING MECHANICAL POWER OR A REACTIVE PROPULSIVE THRUST, NOT OTHERWISE PROVIDED FOR
    • F03D—WIND MOTORS
    • F03D9/00—Adaptations of wind motors for special use; Combinations of wind motors with apparatus driven thereby; Wind motors specially adapted for installation in particular locations
    • F03D9/008—Adaptations of wind motors for special use; Combinations of wind motors with apparatus driven thereby; Wind motors specially adapted for installation in particular locations the wind motor being combined with water energy converters, e.g. a water turbine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F03—MACHINES OR ENGINES FOR LIQUIDS; WIND, SPRING, OR WEIGHT MOTORS; PRODUCING MECHANICAL POWER OR A REACTIVE PROPULSIVE THRUST, NOT OTHERWISE PROVIDED FOR
    • F03B—MACHINES OR ENGINES FOR LIQUIDS
    • F03B13/00—Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates
    • F03B13/12—Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy
    • F03B13/26—Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy using tide energy
    • F03B13/264—Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy using tide energy using the horizontal flow of water resulting from tide movement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
    • F05B—INDEXING SCHEME RELATING TO WIND, SPRING, WEIGHT, INERTIA OR LIKE MOTORS, TO MACHINES OR ENGINES FOR LIQUIDS COVERED BY SUBCLASSES F03B, F03D AND F03G
    • F05B2220/00—Application
    • F05B2220/30—Application in turbines
    • F05B2220/32—Application in turbines in water turbines
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F05—INDEXING SCHEMES RELATING TO ENGINES OR PUMPS IN VARIOUS SUBCLASSES OF CLASSES F01-F04
    • F05B—INDEXING SCHEME RELATING TO WIND, SPRING, WEIGHT, INERTIA OR LIKE MOTORS, TO MACHINES OR ENGINES FOR LIQUIDS COVERED BY SUBCLASSES F03B, F03D AND F03G
    • F05B2220/00—Application
    • F05B2220/70—Application in combination with
    • F05B2220/706—Application in combination with an electrical generator
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/20—Hydro energy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/30—Energy from the sea, e.g. using wave energy or salinity gradient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/70—Wind energy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/70—Wind energy
    • Y02E10/72—Wind turbines with rotation axis in wind direction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Mechanical Engineering (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Combustion & Propulsion (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Sustainable Development (AREA)
  • Power Engineering (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)

Abstract

processo para a síntese e forma cristalina de agomelatina e composições farmacêuticas contendo-a. a presente invenção refere-se a um processo para a síntese industrial e nova forma cristalina do composto de fórmula (i) medicamentos. aplicação na síntese de agomelatina.
BRPI0500393A 2004-02-13 2005-02-14 forma cristalina ii de agomelatina e sua composição farmacêutica BRPI0500393B8 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122018068717A BR122018068717B8 (pt) 2004-02-13 2005-02-14 processos para a síntese de agomelatina
TW095120045A TW200716511A (en) 2004-02-13 2006-06-06 New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0401439A FR2866335B1 (fr) 2004-02-13 2004-02-13 Nouveau procede de synthese de l'agomelatine
FR0401439 2004-02-13

Publications (3)

Publication Number Publication Date
BRPI0500393A BRPI0500393A (pt) 2005-09-27
BRPI0500393B1 BRPI0500393B1 (pt) 2020-12-22
BRPI0500393B8 true BRPI0500393B8 (pt) 2021-05-25

Family

ID=34685019

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018068717A BR122018068717B8 (pt) 2004-02-13 2005-02-14 processos para a síntese de agomelatina
BRPI0500393A BRPI0500393B8 (pt) 2004-02-13 2005-02-14 forma cristalina ii de agomelatina e sua composição farmacêutica

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018068717A BR122018068717B8 (pt) 2004-02-13 2005-02-14 processos para a síntese de agomelatina

Country Status (40)

Country Link
US (2) US7250531B2 (pt)
EP (1) EP1564202B1 (pt)
JP (1) JP4316517B2 (pt)
KR (1) KR100692776B1 (pt)
CN (2) CN1321106C (pt)
AP (1) AP1839A (pt)
AR (1) AR047741A1 (pt)
AT (1) ATE407921T1 (pt)
AU (2) AU2005200616B8 (pt)
BR (2) BR122018068717B8 (pt)
CA (1) CA2495967C (pt)
CR (1) CR7680A (pt)
CU (1) CU23515A3 (pt)
CY (1) CY1108445T1 (pt)
DE (1) DE602005009585D1 (pt)
DK (1) DK1564202T3 (pt)
EA (1) EA008473B1 (pt)
EC (1) ECSP055601A (pt)
ES (1) ES2314588T3 (pt)
FR (1) FR2866335B1 (pt)
GE (1) GEP20074133B (pt)
HR (1) HRP20080537T3 (pt)
IL (1) IL166815A (pt)
MA (1) MA27518A1 (pt)
ME (1) ME01364B (pt)
MX (1) MXPA05001637A (pt)
MY (1) MY138452A (pt)
NO (1) NO333500B1 (pt)
NZ (1) NZ538191A (pt)
PL (1) PL1564202T3 (pt)
PT (1) PT1564202E (pt)
RS (1) RS50662B (pt)
SA (1) SA05260001B1 (pt)
SG (1) SG114703A1 (pt)
SI (1) SI1564202T1 (pt)
TW (1) TW200716511A (pt)
UA (1) UA78825C2 (pt)
UY (1) UY28747A1 (pt)
WO (1) WO2005077887A1 (pt)
ZA (1) ZA200501257B (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498466B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
FR2866334B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine
US7498465B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
FR2889522B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
US7635721B2 (en) 2005-08-03 2009-12-22 Les Laboratoires Servier Crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7645905B2 (en) 2005-08-03 2010-01-12 Les Laboratoires Servier Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
US7358395B2 (en) 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
FR2889523B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) * 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2890562B1 (fr) * 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2894475B1 (fr) * 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
FR2899472B1 (fr) * 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
CN101161638B (zh) * 2006-10-13 2010-09-29 北京德众万全药物技术开发有限公司 一种新的阿戈美拉汀重要中间体的制备方法
FR2908994B1 (fr) * 2006-11-24 2009-04-03 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement de la leucomalacie periventriculaire
FR2908995B1 (fr) * 2006-11-24 2009-02-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
CA2685924A1 (en) * 2007-05-01 2008-11-13 Concert Pharmaceuticals Inc. Naphthyl(ethyl)acetamides
US20080280991A1 (en) * 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted naphthalenes
JP2009013074A (ja) * 2007-06-30 2009-01-22 Lab Servier 全般性不安障害の処置を目的とする医薬を得るためのアゴメラチンの使用
FR2919606B1 (fr) 2007-08-03 2010-09-17 Servier Lab Nouveau procede de synthese du (7-methoxy-1-naphtyl) acetonitrile et application a la synthese de l'agomelatine.
FR2923482B1 (fr) * 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN101638376B (zh) 2008-07-29 2011-04-27 江苏恩华药业股份有限公司 阿戈美拉汀的制备方法及其中间体
FR2934859B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2934855B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2934857B1 (fr) * 2008-08-05 2010-08-27 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2934856B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede d'obtention de la forme cristalline v de l'agomelatine
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) * 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN102001959B (zh) * 2009-09-01 2014-07-02 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
CN102050756A (zh) * 2009-11-09 2011-05-11 北京利乐生制药科技有限公司 阿戈美拉汀新晶型及其制备方法
EP2319827A1 (en) 2009-11-09 2011-05-11 Ratiopharm GmbH Process for the production of polymorph form I of agomelatine
CN101704763B (zh) * 2009-11-25 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀i型晶体的制备方法
CN101709036B (zh) * 2009-12-17 2012-07-04 天津药物研究院 阿戈美拉汀中间体2-(7-甲氧基-1-萘基)乙胺的制备
TW201139370A (en) 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
CN101781226B (zh) * 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN102146046B (zh) * 2010-02-05 2013-07-03 天津市汉康医药生物技术有限公司 一种n-[2-(7-甲氧基-1-萘基)乙基]乙酰胺新的制备方法
FR2956031B1 (fr) * 2010-02-11 2012-03-02 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble obsessionnel compulsif (toc)
CN101792400B (zh) * 2010-03-16 2013-01-30 华东师范大学 一种阿戈美拉汀的合成方法
EP2558440B1 (en) 2010-04-15 2016-11-16 ratiopharm GmbH Process for the production of polymorph form i of agomelatine
CN101870662B (zh) * 2010-05-21 2013-03-20 中山大学 结晶型阿戈美拉汀溶剂化物及其制备方法
CN102276492B (zh) * 2010-06-08 2013-04-10 上海医药工业研究院 阿戈美拉汀中间体及其制备方法
EP2580183B1 (en) 2010-06-10 2014-07-23 Gador S.A. New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide
CN102229541A (zh) * 2010-09-17 2011-11-02 福建广生堂药业有限公司 阿戈美拉汀n-[2-(7-甲氧基萘-1-基)乙基]乙酰胺的制备方法
CN102452951B (zh) * 2010-10-25 2014-02-19 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
CN102030673B (zh) * 2010-11-24 2014-04-23 威海迪素制药有限公司 一种阿戈美拉汀新晶型及制备方法
CN102531956B (zh) * 2010-12-21 2014-07-09 浙江九洲药业股份有限公司 用于制备阿戈美拉汀的中间体及相关制备方法
EP2705023A4 (en) * 2011-01-04 2014-11-19 Symed Labs Ltd PROCESSES FOR THE PREPARATION OF N- [2- (7-METHOXY-1-NAPHTHYLLELYHYL) ACETAMIDE
FR2970001B1 (fr) 2011-01-05 2013-01-04 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2970000B1 (fr) * 2011-01-05 2013-01-04 Servier Lab Nouveau procede de synthese de l'agomelatine
CZ303787B6 (cs) 2011-01-21 2013-05-02 Zentiva, K.S. Metastabilní krystalové formy agomelatinu a jejich farmaceutické kompozice
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
WO2012127483A1 (en) * 2011-03-24 2012-09-27 Symed Labs Limited Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide
WO2012130837A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
FR2976284B1 (fr) * 2011-06-09 2013-05-24 Servier Lab Nouveaux co-cristaux d'agomelatine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
ITMI20111078A1 (it) 2011-06-15 2012-12-16 Laboratorio Chimico Int Spa Procedimento per la preparazione di forme cristalline dell?agomelatina e nuovo polimorfo
WO2013018100A1 (en) * 2011-08-01 2013-02-07 Symed Labs Limited A process for the preparation of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide crystalline form i
WO2013017903A1 (en) 2011-08-03 2013-02-07 Laboratorio Chimico Internazionale S.P.A. Process for the preparation of crystalline form i of agomelatine
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2562151A1 (en) * 2011-08-25 2013-02-27 Dr. Reddy's Laboratories Ltd. Processes for the preparation of agomelatine and its intermediates
CN102367228A (zh) * 2011-10-24 2012-03-07 南京工业大学 一种合成阿戈美拉汀的方法
WO2013082302A1 (en) 2011-11-30 2013-06-06 Ratiopharm Gmbh Agomelatine-urea complex and crystalline forms thereof
CZ2012108A3 (en) 2012-02-15 2013-02-27 Zentiva Ks A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine
CN103319370B (zh) * 2012-03-21 2016-08-03 黑龙江福和华星制药集团股份有限公司 一种(7-甲氧基-1-萘基)乙腈的制备方法
KR20150020191A (ko) 2012-05-14 2015-02-25 상하이 라이트핸드 팜테크 주식회사 아고멜라틴 산기 복합체와 그의 제조방법 및 용도
CA2877410A1 (en) 2012-07-16 2014-01-23 Ratiopharm Gmbh Complex of agomelatine and cyclodextrin
ITMI20121444A1 (it) 2012-08-27 2014-02-28 Procos Spa Processo per la produzione di agomelatine
CN102838504A (zh) * 2012-09-12 2012-12-26 福建广生堂药业股份有限公司 一种阿戈美拉汀的新晶型l及其制备方法
CN102875408B (zh) * 2012-10-09 2014-07-16 江西同和药业有限责任公司 一种阿戈美拉汀的制备方法
WO2014056421A1 (zh) * 2012-10-09 2014-04-17 江西同和药业有限责任公司 1-氰基-1-（7-甲氧基-1-萘基）甲醇酯类化合物及其制备方法和应用
EP2909166A4 (en) * 2012-10-22 2016-10-26 Symed Labs Ltd PROCESS FOR THE PREPARATION OF AGOMALATIN USING NEW INTERMEDIATES
WO2014072998A1 (en) 2012-11-07 2014-05-15 Cadila Healthcare Limited An improved process for preparation of agomelatine
CN102942501B (zh) * 2012-12-10 2015-08-19 天津泰普药品科技发展有限公司 一种氢化制备阿戈美拉汀的生产方法
EP2743255B1 (en) 2012-12-17 2016-06-22 Dr. Reddy's Laboratories Ltd. Cocrystal of agomelatine with phosphoric acid
WO2014096373A1 (en) 2012-12-21 2014-06-26 Laboratorios Lesvi, S. L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
CN104130154A (zh) * 2013-05-03 2014-11-05 郭炳华 一种制备高纯度阿戈美拉汀的方法
PL2810656T3 (pl) 2013-06-06 2018-01-31 Zentiva Ks Preparaty agomelatyny zawierające agomelatynę w postaci kokryształów
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
ES2863977T3 (es) * 2013-07-04 2021-10-13 Pharmathen Sa Un nuevo procedimiento para la preparación de derivados de tetralina y naftaleno
CZ2013621A3 (cs) 2013-08-13 2015-02-25 Zentiva, K.S. Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci
FR3014434B1 (fr) 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
FR3014437B1 (fr) * 2013-12-05 2016-12-23 Servier Lab Nouveau procede de synthese de l'agomelatine
FR3014433B1 (fr) 2013-12-05 2015-12-25 Servier Lab Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
PL3075724T3 (pl) 2015-03-31 2023-12-27 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Stała postać agomelatyny
WO2017005954A1 (es) * 2015-07-03 2017-01-12 Universidad De Granada Análogos de la melatonina para el tratamiento del cáncer
CN105601537B (zh) * 2016-01-25 2018-11-06 江西同和药业股份有限公司 一种2-(7-甲氧基-1-萘基)乙腈的制备方法
CN105669494A (zh) * 2016-03-11 2016-06-15 上海韬鸿化工科技有限公司 一种2-(7-甲氧基-1-萘基)乙氰的制备方法
FR3056211B1 (fr) 2016-09-19 2018-09-07 Servier Lab Nouveau procede de synthese de l'agomelatine
CN106928082A (zh) * 2016-12-27 2017-07-07 湖南天济草堂制药股份有限公司 一种新的阿戈美拉汀合成及纯化方法
CN107382773A (zh) * 2017-06-19 2017-11-24 太仓弘杉环保科技有限公司 一种合成7‑甲氧基萘乙腈的方法
CN107162933A (zh) * 2017-06-19 2017-09-15 太仓大唐化纤厂 一种合成阿戈美拉汀重要中间体7‑甲氧基萘乙腈的方法
EP3466923A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Process for the preparation of agomelatine in crystalline form
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof
CN117304053A (zh) * 2022-06-22 2023-12-29 北京海美源医药科技有限公司 一种阿戈美拉汀和/或其中间体的纯化方法和其应用
EP4342879A1 (en) 2022-09-21 2024-03-27 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Very efficient process for the preparation of agomelatine
CN117776934A (zh) * 2023-12-22 2024-03-29 江苏威奇达药业有限公司 一种阿戈美拉汀中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327022A (en) * 1973-08-16 1982-04-27 Sterling Drug Inc. Heterocyclic alkyl naphthols
US3931188A (en) * 1974-05-06 1976-01-06 Bristol-Myers Company 3-Hydroxy-5,6-benzomorphinan derivatives
US3992403A (en) * 1975-05-30 1976-11-16 Schering Corporation 2-Imidazolines and their use as hypoglycemic agents
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2737725B1 (fr) * 1995-08-08 1997-10-31 Valentonine Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament
US20050164987A1 (en) * 2003-12-24 2005-07-28 Barberich Timothy J. Melatonin combination therapy for improving sleep quality

Also Published As

Publication number Publication date
WO2005077887A1 (fr) 2005-08-25
EP1564202A1 (fr) 2005-08-17
EA200500203A1 (ru) 2005-08-25
NO20050741D0 (no) 2005-02-11
DE602005009585D1 (de) 2008-10-23
CR7680A (es) 2008-09-23
AR047741A1 (es) 2006-02-15
US20070197829A1 (en) 2007-08-23
CN1321106C (zh) 2007-06-13
PL1564202T3 (pl) 2009-02-27
EP1564202B1 (fr) 2008-09-10
US20050182276A1 (en) 2005-08-18
PT1564202E (pt) 2008-10-22
DK1564202T3 (da) 2008-12-15
JP4316517B2 (ja) 2009-08-19
CU23515A3 (es) 2010-05-19
AP1839A (en) 2008-04-10
ATE407921T1 (de) 2008-09-15
MY138452A (en) 2009-06-30
UA78825C2 (en) 2007-04-25
EA008473B1 (ru) 2007-06-29
JP2005247844A (ja) 2005-09-15
ME01364B (me) 2010-06-30
NO20050741L (no) 2005-08-15
GEP20074133B (en) 2007-06-25
CA2495967A1 (fr) 2005-08-13
HK1078563A1 (en) 2006-03-17
RS50662B (sr) 2010-06-30
ZA200501257B (en) 2005-11-30
AP2005003221A0 (en) 2005-03-31
CN101041629B (zh) 2010-10-13
CN101041629A (zh) 2007-09-26
MA27518A1 (fr) 2005-09-01
AU2010207746B2 (en) 2012-01-19
FR2866335A1 (fr) 2005-08-19
IL166815A (en) 2010-04-29
US7250531B2 (en) 2007-07-31
BRPI0500393A (pt) 2005-09-27
CY1108445T1 (el) 2014-04-09
KR100692776B1 (ko) 2007-03-12
TW200716511A (en) 2007-05-01
AU2005200616B2 (en) 2010-08-19
US7544839B2 (en) 2009-06-09
ES2314588T3 (es) 2009-03-16
SA05260001B1 (ar) 2009-11-11
HRP20080537T3 (en) 2008-12-31
UY28747A1 (es) 2005-10-31
KR20060042943A (ko) 2006-05-15
SG114703A1 (en) 2005-09-28
IL166815A0 (en) 2006-01-15
MXPA05001637A (es) 2005-08-19
CN1680284A (zh) 2005-10-12
FR2866335B1 (fr) 2006-05-26
NZ538191A (en) 2005-12-23
ECSP055601A (es) 2005-11-22
AU2005200616B8 (en) 2010-09-02
AU2010207746A1 (en) 2010-08-26
BR122018068717B8 (pt) 2021-07-27
BRPI0500393B1 (pt) 2020-12-22
SI1564202T1 (sl) 2008-12-31
BR122018068717B1 (pt) 2019-11-05
AU2005200616A1 (en) 2005-09-01
NO333500B1 (no) 2013-06-24
CA2495967C (fr) 2008-01-22
HK1107081A1 (zh) 2008-03-28

Similar Documents

Publication Publication Date Title
BRPI0500393B8 (pt) forma cristalina ii de agomelatina e sua composição farmacêutica
BRPI0603074A (pt) forma cristalina iii de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0603059A (pt) forma cristalina v de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0603043A (pt) forma cristalina iv de agomelatina, um processo para sua preparação e composições farmacêuticas contendo-a
BRPI0600796B8 (pt) forma gama-cristalina de cloridrato de ivabradina, processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
BRPI0600795B8 (pt) forma betad-cristalina de cloridrato de ivabradina, um processo para preparação do mesmo e composições farmacêuticas contendo o mesmo
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
ECSP088859A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
BRPI0717970C1 (pt) composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto
CY1109737T1 (el) Νεα μεθοδος συνθεσης του (7-μεθοξυ-1-ναφθυλ) ακετονιτριλιου και εφαρμογη στη συνθεση της αγομελατινης
UY29510A1 (es) Derivados de urea, metodos para su fabricación, y usos de los mismos
EA201000257A1 (ru) Новый способ синтеза (7-метокси-l-нафтил) ацетонитрила и применение в синтезе агомелатина
UY30787A1 (es) "inhibidores benzoimidazolicos de trpv1"
BRPI0803636A2 (pt) processo para a sìntese de ranelato de estrÈncio e seus hidratos
BRPI0502228A (pt) forma cristalina alfa de ranelato de estrÈncio, processo para sua preparação, e composições farmacêuticas que a contêm
GEP20084470B (en) New phenylpyridinylpiperazine compounds, a process for their preparation and pharmaceutical compositions containing them
BRPI0606659A2 (pt) processos para a preparação de álcoois aminoetoxibenzìlicos
BRPI0518487A2 (pt) carboxamidas e seu uso
BRPI0602206A (pt) forma polimórfica de dexcetoprofeno trometamol, sua preparação e composições que a contêm
BRPI0702817A (pt) compostos de naftaleno, processo para sua preparação e composições farmacêuticas que contêm esses compostos
BRPI0502037B8 (pt) processo para a síntese de (7-metóxi-1-naftil)acetonitrila e sua aplicação na síntese de agomelatina
BRPI0702769A (pt) compostos de naftaleno, processo para sua preparação e composições farmacêuticas contendo os mesmos
ECSP088489A (es) Prodrogas de sulfonato de sulfamoilo

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B15N Others concerning applications: notification of judicial decision

Free format text: INPI NO 52400.148695/2018-38 NUP: 00408.046654/2018-34 (REF. 5010114-11.2018.4.02.5101) 25A VARA FEDERAL DO RIO DE JANEIRO IMPETRANTE: LES LABORATOIRES SERVIER IMPETRADO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI DECISAO: NEGAR PROVIMENTO A REMESSA NECESSARIA E DAR PROVIMENTO A APELACAO, PARA DETERMINAR AO INPI QUE EXECUTE NO PRAZO DE 60 DIAS CADA ETAPA DO PROCESSO ADMINISTRATIVO DE EXAME, INCLUSIVE DE SEGUNDA INSTANCIA DO PEDIDO DE PATENTE PI0500393-8. A DECISAO/ACORDAO TRANSITOU EM JULGADO EM 04/06/2020.

B15W Others matters related to applications: legal action concerning application

Free format text: INPI NO 52400.148695/2018-38 ORIGEM: 25A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO: 00408.046654/2018-34 (REF. 5010114-11.2018.4.02.5101 SUBJUDICE COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: LES LABORATOIRES SERVIER REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.003844/2022-05 ORIGEM: 1A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1014183-07.2022.4.01.3400 ACAO DE PROCEDIMENTO COMUM AUTOR: LES LABORATOIRES SERVIER REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL